Clinically ineffective reperfusion after endovascular therapy in acute ischemic stroke
Endovascular treatment is a highly effective therapy for acute ischemic stroke due to large
vessel occlusion. However, in clinical practice, nearly half of the patients do not have …
vessel occlusion. However, in clinical practice, nearly half of the patients do not have …
Impact of collaterals on the efficacy and safety of endovascular treatment in acute ischaemic stroke: a systematic review and meta-analysis
Objective We aimed to investigate the role of pretreatment collateral status in predicting the
efficacy and safety of endovascular treatment (EVT) in acute ischaemic stroke due to cervical …
efficacy and safety of endovascular treatment (EVT) in acute ischaemic stroke due to cervical …
Trial of endovascular therapy for acute ischemic stroke with large infarct
X Huo, G Ma, X Tong, X Zhang, Y Pan… - … England Journal of …, 2023 - Mass Medical Soc
Background The role of endovascular therapy for acute stroke with a large infarction has not
been extensively studied in differing populations. Methods We conducted a multicenter …
been extensively studied in differing populations. Methods We conducted a multicenter …
Impact of collateral status on successful revascularization in endovascular treatment: a systematic review and meta-analysis
Background: Pre-treatment collateral status may be associated with the rates of successful
revascularization in acute ischemic stroke patients receiving endovascular treatment (EVT) …
revascularization in acute ischemic stroke patients receiving endovascular treatment (EVT) …
Current status of endovascular treatment for acute large vessel occlusion in China: a real-world nationwide registry
B Jia, Z Ren, M Mokin, WS Burgin, CT Bauer, J Fiehler… - Stroke, 2021 - Am Heart Assoc
Background and Purpose: The benefit of endovascular treatment (EVT) for large vessel
occlusion in clinical practice in developing countries like China needs to be confirmed. The …
occlusion in clinical practice in developing countries like China needs to be confirmed. The …
[HTML][HTML] Exosomes derived from microRNA-138-5p-overexpressing bone marrow-derived mesenchymal stem cells confer neuroprotection to astrocytes following …
Y Deng, D Chen, F Gao, H Lv, G Zhang, X Sun… - Journal of biological …, 2019 - Springer
Background MicroRNAs (miRNAs) are implicated in the progression of ischemic stroke (IS)
and bone marrow-derived mesenchymal stem cells (BMSCs)-derived exosomes play a role …
and bone marrow-derived mesenchymal stem cells (BMSCs)-derived exosomes play a role …
Comparison of drug-eluting stent with bare-metal stent in patients with symptomatic high-grade intracranial atherosclerotic stenosis: a randomized clinical trial
B Jia, X Zhang, N Ma, D Mo, F Gao, X Sun… - JAMA …, 2022 - jamanetwork.com
Importance In-stent restenosis (ISR) is the primary reason for stroke recurrence after
intracranial stenting in patients who were treated with a standard bare-metal stent (BMS) …
intracranial stenting in patients who were treated with a standard bare-metal stent (BMS) …
Efficacy and safety of butylphthalide in patients with acute ischemic stroke: a randomized clinical trial
A Wang, B Jia, X Zhang, X Huo, J Chen, L Gui… - JAMA …, 2023 - jamanetwork.com
Importance DL-3-n-butylphthalide (NBP) is a drug for treating acute ischemic stroke and may
play a neuroprotective role by acting on multiple active targets. The efficacy of NBP in …
play a neuroprotective role by acting on multiple active targets. The efficacy of NBP in …
Thirty-day outcome of a multicenter registry study of stenting for symptomatic intracranial artery stenosis in China
Z Miao, Y Zhang, J Shuai, C Jiang, Q Zhu, K Chen… - Stroke, 2015 - Am Heart Assoc
Background and Purpose—Although recent trials have suggested that stenting is worse than
medical therapy for patients with severe symptomatic intracranial atherosclerotic stenosis, it …
medical therapy for patients with severe symptomatic intracranial atherosclerotic stenosis, it …
Platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban in acute ischemic stroke
M Yang, X Huo, Z Miao, Y Wang - Drugs, 2019 - Springer
Tirofiban is a non-peptide selective glycoprotein (GP) IIb/IIIa receptor inhibitor that reversibly
inhibits fibrinogen-dependent platelet aggregation and subsequent formation of thrombi …
inhibits fibrinogen-dependent platelet aggregation and subsequent formation of thrombi …